Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
about
Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerSystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionEmerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyNeuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).Active immunotherapy induces antibody responses that target tumor angiogenesis.Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible?Translating tumor antigens into cancer vaccinesMicrobiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis.Current status of autologous breast tumor cell-based vaccines.Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma VaccinesSequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumorsDesign and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Cancer vaccines: Looking to the future.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsCytokines in cancer immunotherapy.Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanismsSystemic effects of local radiotherapy.Is cancer gene therapy an empty suit?Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects."Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.Directing dendritic cell immunotherapy towards successful cancer treatment.Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses.Carbohydrate-based cancer vaccines: target cancer with sugar bullets.Antigen-specific vaccines for cancer treatment.Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayIn situ regulation of DC subsets and T cells mediates tumor regression in mice.Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up.Boosting leukemia-specific T cell responses in patients following stem cell transplantation.Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines.Dendritic cell immunotherapy.Evaluation of the diagnostic performance of panfungal polymerase chain reaction assay in invasive fungal diseases.Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
P2860
Q26749451-636BB6BA-E671-4F72-8601-5EE686C13223Q28067023-41E4438C-782D-4436-B44A-AF3B8B311E57Q28383385-213AB58D-29C7-4340-8564-C5BEEF2B6AFDQ30438965-3C252A84-77FA-4978-AD2E-D58AAA74FC74Q31044261-7B07DA66-D5ED-4850-8589-DB9E02AAFC10Q33772446-55BF059B-630D-48B4-91B8-5DE2474F3607Q34364763-5AFE960B-22C4-4F4E-8F4C-06530D67EBF1Q34484042-753B53CD-AA48-4702-B855-B9894E0ED613Q34918999-14FE97ED-245A-429D-B337-C4EFA8241D9FQ35154214-E446672D-4C16-4F14-AECD-0F4CFC77C27CQ35862728-49F9D203-5A11-4128-9BAA-60580BC50322Q35962460-F0EF58E4-8F12-40DF-9948-AA42A0428E6FQ36777133-959E0F52-395C-44C2-9E36-EEE549F63338Q36866158-9AB6175E-1EDB-4672-B635-945A0E8C986CQ37123927-3B08AD81-92FF-4E95-A191-13A4E91B4BDEQ37148152-B31B1CFE-A55C-410B-B6A2-38466DBBD0A9Q37273162-A3EC718D-E2FC-4C53-9272-AEDB28F113B4Q37539309-1689F5D9-33D5-490B-81EF-57EB5168148DQ37564361-8F4B4CFE-B29D-4BC1-A367-0E8CFC8BB48BQ37580862-3A0233FB-3F5E-475B-8EDD-9355446FE4F6Q37622288-5EA5B293-6139-4608-BB84-7163B1784647Q37754014-679EECA6-9655-4F68-8ED2-87068DCCEA78Q37945304-8B41FCF5-5D2C-4EF1-AB21-FB73DA2782F7Q37952804-A34AA582-157D-460B-8618-F6CDA3ED1854Q37963294-E7E20ABE-D861-4FA1-9B00-6774164AC4DCQ38016342-ECF4480A-1A51-46D4-B5C1-2E4C890A7A36Q38284692-E1A5108A-BC2F-410A-B747-4F574EFFE948Q38451287-6207C8B0-71CE-474E-8A59-BB7854B2C2FFQ38731119-40FB5939-4589-495C-B72E-4CCFFF9BCF78Q39532160-15C6608F-7032-4316-BF65-1B287F303F1BQ39704510-B469DB43-0559-446A-9458-699C85A228BFQ39885761-86B77F21-3C84-48CF-A174-5F28699FC4D4Q41842804-B4EF911F-67B1-4580-8EAC-F87A9895CD94Q41882563-446E854A-E7C2-481B-8A6A-76456133048EQ41963849-84A14119-D8B4-4B5B-80C8-2EAF7C1DC32FQ44483910-4E78DFB2-6866-4260-B853-F324B8F71952Q46268475-F6AB9565-7405-4AB0-9952-A5CE7519E25CQ47670865-9B8B32F4-A950-458A-89E5-36A6B1C25E03
P2860
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@en
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@nl
type
label
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@en
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@nl
prefLabel
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@en
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@nl
P2093
P2860
P1476
Enhancing the clinical activit ...... secreting tumor cell vaccines.
@en
P2093
F Stephen Hodi
Glenn Dranoff
Masahisa Jinushi
P2860
P304
P356
10.1111/J.1600-065X.2008.00618.X
P577
2008-04-01T00:00:00Z